reblozyl.com | Anemia in MDS-RS & Beta Thalassemia (BT) Treatment

Robots.txt Information

Robot	Path	Permission
GoogleBot	/	✔
BingBot	/	✔
BaiduSpider	/	✔
YandexBot	/	✔
User-agent: * Disallow: Sitemap:

Meta Tags

Title	Anemia in MDS-RS & Beta Thalassemia (BT) Treatment - REBLOZYL®
Description	Your road to fewer REBLOZYL® (luspatercept-aamt) is a prescription medicine used to treat patients with anemia in myelodysplastic syndromes with ring sideroblasts (MDS-RS) & anemia in beta thalassemia (BT). Please see Indication and Important Safety
Keywords	N/A

Server Information

WebSite	reblozyl.com
Host IP	45.60.150.161
Location	United States

Related Websites

                        Site
                        Rank
                    

More to Explore

reblozyl.com Valuation

US$26,861,464

Last updated: 2023-05-16 12:05:04

reblozyl.com has Semrush global rank of 394,033. reblozyl.com has an estimated worth of US$ 26,861,464, based on its estimated Ads revenue. reblozyl.com receives approximately 3,099,400 unique visitors each day. Its web server is located in United States, with IP address 45.60.150.161. According to SiteAdvisor, reblozyl.com is safe to visit.

Traffic & Worth Estimates

Purchase/Sale Value	US$26,861,464
Daily Ads Revenue	US$24,796
Monthly Ads Revenue	US$743,856
Yearly Ads Revenue	US$8,926,271
Daily Unique Visitors	206,627
Note: All traffic and earnings values are estimates.

DNS Records

Host	Type	TTL	Data
reblozyl.com.	A	59	IP: 45.60.150.161
reblozyl.com.	A	59	IP: 45.60.170.161
reblozyl.com.	NS	21600	NS Record: ns-1346.awsdns-40.org.
reblozyl.com.	NS	21600	NS Record: ns-1763.awsdns-28.co.uk.
reblozyl.com.	NS	21600	NS Record: ns-25.awsdns-03.com.
reblozyl.com.	NS	21600	NS Record: ns-947.awsdns-54.net.
reblozyl.com.	TXT	300	TXT Record: 7d4b4d27c8e74b7b860d78da8dd54cb8
reblozyl.com.	TXT	300	TXT Record: facebook-domain-verification=yp9rxs5ewwtwuc1r2j3wdt6qhcfgtk
reblozyl.com.	TXT	300	TXT Record: google-site-verification=2e0cL6F_kHzgVCvq9eNgLOlzC7uQwBE0Z_6hKOqOOYc

HtmlToTextCheckTime:2023-05-16 12:05:04

Indications Full Prescribing Information Patient Information Healthcare Professional Site Healthcare Professional Site Patient Information BMS Access Support ® Sign Up to Learn More Sign up MDS & Anemia MDS & anemia Role of anemia in MDS Caregiver information About REBLOZYL About REBLOZYL REBLOZYL patient responses Why REBLOZYL? Starting & Staying Starting & staying on REBLOZYL Starting REBLOZYL Tracking your treatment Resources Financial assistance MDS resources Learn more FAQ FAQ Switch to Reblozyl for BT INDICATIONS (1 of 2) REBLOZYL ® (luspatercept-aamt) is a prescription medicine used to treat anemia (low red blood cells) in adults with myelodysplastic syndromes with ring sideroblasts (MDS-RS) or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) who need regular RBC transfusions and have not responded well to or cannot receive an erythropoiesis stimulating agent (ESA). REBLOZYL is not for use as a substitute for RBC transfusions

HTTP Headers

HTTP/1.1 301 Moved Permanently
Location: https://reblozyl.com/
Content-Length: 0
Connection: close

HTTP/2 301 
date: Tue, 25 Jan 2022 11:48:31 GMT
content-type: text/html; charset=iso-8859-1
set-cookie: AWSALBTG=kfvCpujaSjwJ4lUBSCOzvJYIUNjkc2vIHIn145iljYxUVOgDzhT1MUCHZallI+hnB7Bi+5S7qWPS/oCO7l8TYJVzcLTa1s8PV2cfD4bPVRGA2i6RAM+V9VJepLlZEH80dspXMYnO1InhYrioJRgPw4LJ2HnpcQFN0OLaVwvioHmBUJ20Bj4=; Expires=Tue, 01 Feb 2022 11:48:31 GMT; Path=/
set-cookie: AWSALBTGCORS=kfvCpujaSjwJ4lUBSCOzvJYIUNjkc2vIHIn145iljYxUVOgDzhT1MUCHZallI+hnB7Bi+5S7qWPS/oCO7l8TYJVzcLTa1s8PV2cfD4bPVRGA2i6RAM+V9VJepLlZEH80dspXMYnO1InhYrioJRgPw4LJ2HnpcQFN0OLaVwvioHmBUJ20Bj4=; Expires=Tue, 01 Feb 2022 11:48:31 GMT; Path=/; SameSite=None; Secure
server: Apache
location: https://www.reblozyl.com/
set-cookie: AWSALBAPP-0=_remove_; Expires=Tue, 01 Feb 2022 11:48:31 GMT; Path=/; SameSite=None; Secure
set-cookie: AWSALBAPP-1=_remove_; Expires=Tue, 01 Feb 2022 11:48:31 GMT; Path=/; SameSite=None; Secure
set-cookie: AWSALBAPP-2=_remove_; Expires=Tue, 01 Feb 2022 11:48:31 GMT; Path=/; SameSite=None; Secure
set-cookie: AWSALBAPP-3=_remove_; Expires=Tue, 01 Feb 2022 11:48:31 GMT; Path=/; SameSite=None; Secure
set-cookie: visid_incap_2613599=0q3ObTD2Sn2H50QW8pWpeo7j72EAAAAAQUIPAAAAAADH4KWZ6pfOo3lvVMqxFcFP; expires=Wed, 25 Jan 2023 10:59:55 GMT; HttpOnly; path=/; Domain=.reblozyl.com
set-cookie: incap_ses_1214_2613599=mQjUYZfvCyXVO/l5Ef/YEI/j72EAAAAAEqjObdS2a7GZcY1xwKXuuQ==; path=/; Domain=.reblozyl.com
x-cdn: Imperva
x-iinfo: 1010-40991952-40991953 nNNN RT(1643111310748 0) q(0 0 2 0) r(3 4) U6

HTTP/2 200 
date: Tue, 25 Jan 2022 11:48:32 GMT
content-type: text/html; charset=UTF-8
set-cookie: AWSALBTG=3n1pnDE0czH2pIgvabhfpgj932Bd3pppymSnaVgKNc88euoSNYWq3drp9lNy43OmESWhYiOMP5EKwLTrHcDmX4tlbfqitTZ2+MCcWiKs2w4/ifuz2ICswwo+32iwEYkrfiJBvGrn3DwtoVziA2Zq7VQGGZUB/tOXSewvFPD4dQaehdcPLHs=; Expires=Tue, 01 Feb 2022 11:48:32 GMT; Path=/
set-cookie: AWSALBTGCORS=3n1pnDE0czH2pIgvabhfpgj932Bd3pppymSnaVgKNc88euoSNYWq3drp9lNy43OmESWhYiOMP5EKwLTrHcDmX4tlbfqitTZ2+MCcWiKs2w4/ifuz2ICswwo+32iwEYkrfiJBvGrn3DwtoVziA2Zq7VQGGZUB/tOXSewvFPD4dQaehdcPLHs=; Expires=Tue, 01 Feb 2022 11:48:32 GMT; Path=/; SameSite=None; Secure
server: Apache
link: ; rel="https://api.w.org/"
link: ; rel="alternate"; type="application/json"
link: ; rel=shortlink
x-xss-protection: 1; mode=block
set-cookie: AWSALBAPP-0=_remove_; Expires=Tue, 01 Feb 2022 11:48:32 GMT; Path=/; SameSite=None; Secure
set-cookie: AWSALBAPP-1=_remove_; Expires=Tue, 01 Feb 2022 11:48:32 GMT; Path=/; SameSite=None; Secure
set-cookie: AWSALBAPP-2=_remove_; Expires=Tue, 01 Feb 2022 11:48:32 GMT; Path=/; SameSite=None; Secure
set-cookie: AWSALBAPP-3=_remove_; Expires=Tue, 01 Feb 2022 11:48:32 GMT; Path=/; SameSite=None; Secure
set-cookie: visid_incap_2613599=hOVDjxmkQ7W63rD3cdtX0JDj72EAAAAAQUIPAAAAAADquh7iZeQFZ9WU8QbeZ5iS; expires=Wed, 25 Jan 2023 08:07:21 GMT; HttpOnly; path=/; Domain=.reblozyl.com
set-cookie: incap_ses_247_2613599=xCVHUxJHdzCvSbRX64VtA5Dj72EAAAAAO4ZXNJGAQtM6aOHUTMLHQQ==; path=/; Domain=.reblozyl.com
x-cdn: Imperva
x-iinfo: 1-21657143-21657144 nNNN RT(1643111312019 0) q(0 0 0 0) r(0 6) U6

reblozyl.com Whois Information

Domain Name: REBLOZYL.COM
Registry Domain ID: 2267061281_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.corporatedomains.com
Registrar URL: http://cscdbs.com
Updated Date: 2021-05-20T05:10:31Z
Creation Date: 2018-05-24T11:23:04Z
Registry Expiry Date: 2022-05-24T11:23:04Z
Registrar: CSC Corporate Domains, Inc.
Registrar IANA ID: 299
Registrar Abuse Contact Email: domainabuse@cscglobal.com
Registrar Abuse Contact Phone: 8887802723
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS-1346.AWSDNS-40.ORG
Name Server: NS-1763.AWSDNS-28.CO.UK
Name Server: NS-25.AWSDNS-03.COM
Name Server: NS-947.AWSDNS-54.NET
DNSSEC: unsigned
>>> Last update of whois database: 2022-01-25T08:11:30Z <<<

reblozyl.com valuation and analysis